Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
- PMID: 30185793
- PMCID: PMC6125482
- DOI: 10.1038/s41398-018-0191-x
Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
Abstract
The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This study aimed to determine the effects of THC and CBD, both alone and in combination on psychotic symptoms and memory function. A randomised, double-blind crossover design compared the effects of (i) placebo, (ii) THC 8 mg, (iii) CBD 16 mg and (iv) THC 8 mg + CBD 16 mg administered by inhalation through a vaporiser. Using an experimental medicine approach to predict treatment sensitivity, we selected 48 cannabis users from the community on the basis of (1) schizotypal personality questionnaire scores (low, high) and (2) frequency of cannabis use (light, heavy). The Brief Psychiatric Rating Scale (BPRS), Psychotomimetic States Inventory (PSI), immediate and delayed prose recall (episodic memory), 1- and 2-back (working memory) were assessed on each day. Results indicated that THC increased overall scores on the PSI, negative symptoms on BPRS, and robustly impaired episodic and working memory. Co-administration of CBD did not attenuate these effects. CBD alone reduced PSI scores in light users only. At a ratio of 2:1, CBD does not attenuate the acute psychotic and memory impairing effects of vaporised THC. Frequent cannabis users may show a blunted anti- psychotic response to CBD, which is of concern due to the high rates of cannabis use disorders in patients with schizophrenia.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Comment in
-
Lost in translation: an overinterpretation of the acute effects of cannabinoids.Transl Psychiatry. 2019 Dec 18;9(1):342. doi: 10.1038/s41398-019-0669-1. Transl Psychiatry. 2019. PMID: 31852882 Free PMC article. No abstract available.
Similar articles
-
The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.Addiction. 2023 Jul;118(7):1282-1294. doi: 10.1111/add.16154. Epub 2023 Feb 26. Addiction. 2023. PMID: 36750134 Free PMC article. Clinical Trial.
-
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014. Epub 2014 Dec 5. Eur Neuropsychopharmacol. 2015. PMID: 25534187 Free PMC article. Clinical Trial.
-
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.Psychol Med. 2012 Feb;42(2):391-400. doi: 10.1017/S0033291711001322. Epub 2011 Jul 29. Psychol Med. 2012. PMID: 21798112
-
A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.Molecules. 2020 Oct 25;25(21):4930. doi: 10.3390/molecules25214930. Molecules. 2020. PMID: 33113776 Free PMC article. Review.
-
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.Neuropsychopharmacology. 2018 Jan;43(1):142-154. doi: 10.1038/npp.2017.209. Epub 2017 Sep 6. Neuropsychopharmacology. 2018. PMID: 28875990 Free PMC article. Review.
Cited by
-
Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial.Sci Rep. 2024 Jul 13;14(1):16163. doi: 10.1038/s41598-024-66879-0. Sci Rep. 2024. PMID: 39003387 Free PMC article. Clinical Trial.
-
A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids.Front Psychiatry. 2024 Jun 10;15:1322434. doi: 10.3389/fpsyt.2024.1322434. eCollection 2024. Front Psychiatry. 2024. PMID: 38915848 Free PMC article. Review.
-
The Development of Cannabinoids as Therapeutic Agents in the United States.Pharmacol Rev. 2024 Aug 15;76(5):915-955. doi: 10.1124/pharmrev.123.001121. Pharmacol Rev. 2024. PMID: 38849155 Review.
-
Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen.Front Psychiatry. 2024 Apr 23;15:1386263. doi: 10.3389/fpsyt.2024.1386263. eCollection 2024. Front Psychiatry. 2024. PMID: 38716117 Free PMC article. Review.
-
Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC).Neuropsychopharmacology. 2024 Aug;49(9):1425-1436. doi: 10.1038/s41386-024-01847-w. Epub 2024 Mar 25. Neuropsychopharmacology. 2024. PMID: 38528133 Free PMC article.
References
-
- UNODC. United Nations Office on Drugs and Crime. World Drug Report 2016.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
